Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MRSO's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was 円0 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was 円-30 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
MRSO's annualizedROC % for the quarter that ended in Jun. 2026 was 0.00%.
MRSO's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 0.00%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
MRSO's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -2.02%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRSO EBIT Related Terms
MRSO EBIT Historical Data
* Premium members only.
The historical data trend for MRSO's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, MRSO's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRSO EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRSO's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MRSO's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRSO (TSE:5619) has a EBIT of 円-30 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MRSO.
Is MRSO's EBIT too high?
MRSO's current EBIT is 円-30 Mil. Overall, MRSO has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MRSO's EBIT compare to VEEV and BTSG?
MRSO's EBIT of 円-30 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MRSO. MRSO's current EBIT is 円-30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRSO stock overvalued right now?
Based on GuruFocus' analysis, MRSO (TSE:5619) is currently considered Significantly Overvalued. The stock's GF Value™ is 円668.03, compared to a current price of 円905.00 — trading 35.5% above its estimated fair value. The current EBIT is 円-30 Mil. MRSO's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MRSO (TSE:5619), the current EBIT is 円-30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRSO (TSE:5619) Overvalued in 2026?
Based on GuruFocus' analysis, MRSO stock appears to be overvalued.
The current stock price of 円905.00 is trading 35.5% above its estimated GF Value™ of 円668.03.
GuruFocus considers MRSO to be Significantly Overvalued.
Key valuation signals for TSE:5619:
EBIT: 円-30 Mil
GF Value™: 円668.03 vs. price of 円905.00 (35.5% above fair value)
No single metric tells the full story. See the TSE:5619 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRSO Inc operates a healthcare platform and provides vertical SaaS solutions for medical institutions, government entities, and corporations. The company offers a preventive medical platform that enables reservations for medical checkups and various cancer screenings. It also provides administrative DX services that support tasks carried out by local governments, including the acceptance of reservations for resident health checkups and vaccinations. These administrative DX services are used by local governments across regions with varying population sizes.
40GF Score
Get the complete analysis for TSE:5619
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:5619 has been successfully added to your 
